This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing Nektar's New Data from REZOLVE-AD Phase 2b Study of Rezpegaldesleukin for Moderate-to-Severe Atopic Dermatitis

Ticker(s): NKTR, LLY, REGN

Who's the expert?

Institution: Harvard

  • Associate Professor of Dermatology at Harvard Medical School and Vice Chair of Clinical Trials and Innovation at Brigham and Women’s Hospital, specializing in alopecia areata and complex medical dermatology.

  • Currently manages over 150 patients with alopecia areata.

  • Medical Director of the Dermatology Consult Service and Co-Director of the Complex Medical Dermatology Fellowship Program, with over 7,500 citations for research on diagnostic testing and health disparities.

Interview Questions
Q1.

How many patients do you manage with moderate-to-severe atopic dermatitis?

Added By: lilly_admin
Q2.

On a scale from 1-10 (10 being extremely excited), where would you rate your level of excitement for rezpegaldesleukin as a treatment for moderate-to-severe atopic dermatitis?

Added By: lilly_admin
Q3.

Rezpegaldesleukin achieved statistically significant improvements across all primary and key secondary endpoints at week 16, including EASI, vIGA-AD, and Itch NRS. How do these results position IL-2 pathway agonism as a potential new mechanism in the treatment of moderate-to-severe atopic dermatitis?

Added By: lilly_admin
Q4.

The study showed rapid onset of action, with clinical benefit emerging after only a few doses. How clinically meaningful is this early response, and how might it compare to the onset timelines observed with currently approved biologics or JAK inhibitors?

Added By: lilly_admin
Q5.

Patients crossing over from placebo to high-dose rezpegaldesleukin demonstrated deepening responses—EASI-75 increasing to 62% and vIGA-AD 0/1 to 38% by week 24. What does this durability and deepening of effect suggest about the potential advantages of extended Treg stimulation?

Added By: lilly_admin
Q6.

High-dose rezpegaldesleukin showed strong patient-reported outcome improvements, including a 72% DLQI response and 67% ADCT response. How important are these quality-of-life metrics in assessing the real-world value of emerging therapies for atopic dermatitis?

Added By: lilly_admin
Q7.

The safety profile over the 16-week induction period was consistent with previous studies, with no increase in serious adverse events versus placebo. Given the chronic nature of atopic dermatitis, how do you interpret these findings in terms of long-term tolerability and future maintenance regimens?

Added By: lilly_admin

Are You Interested In These Questions?

Slingshot Insights Explained
5Days Left to Join Project
Call Date
Oct 15, 2025
Call Time
01:00 PM EDT
Wall Street Time

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.